New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Celldex Therapeutics, Inc.
CLDX
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

2B

Biotechnology

Next Earning date - 07 Nov 2024

2B

Biotechnology

Next Earning date - 07 Nov 2024

26.95USD
Shape-1.18 ( -4.19%)
favorite-chart

Relative Strenght

22
favorite-chart

Volume Buzz

-40%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

49%

Quote Panel

Shape
Updated October 27, 2024
1W -6.06 % 1M -20.71 % 3M -35.82 % 1Y 18.72 %

Key Metrics

Shape
  • Market Cap

    1.79B


  • Shares Outstanding

    66.29M


  • Share in Float

    64.21M


  • Dividende

    0


  • Earning Date

    07 Nov 2024


  • Price Target

    26.95


  • Average Volume

    1.01M


  • Beta

    1.549


  • Range

    22.11-53.18


  • Industry

    Biotechnology


  • Website

    https://www.celldex.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

215.18x

P/S Ratio

2.19x

P/B Ratio

0.0

Debt/Equity

-1809.4%

Net Margin

$-2.8

EPS

How CLDX compares to sector?

P/E Ratio

Relative Strength

Shape

CLDX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$3M

Shape39%

2025-Revenue

$2.94

Shape-444%

2025-EPS

$3M

Shape92%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Citigroup

initialise

Previous: Not converted

2024-10-07

Now: Buy

Goldman Sachs

initialise

Previous: Not converted

2024-09-30

Now: Neutral

Leerink Partners

downgrade

Previous: Not converted

2024-09-27

Now: Market Perform

Wolfe Research

downgrade

Previous: Buy

2024-09-26

Now: Peer Perform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.57
vs -0.39

Q4.22

arrow
arrow

N/A

-0.56
vs -0.43

Q1.23

arrow
arrow

N/A

-0.62
vs -0.49

Q2.23

arrow
arrow

N/A

-0.65
vs -0.58

Q3.23

arrow
arrow

N/A

-0.81
vs -0.57

Q4.23

arrow
arrow

N/A

-0.57
vs -0.56

Q1.24

arrow
arrow

N/A

-0.56
vs -0.62

Q2.24

arrow
arrow

N/A

-0.54
vs -0.65

Q3.24

arrow
arrow

N/A

-0.67
vs -0.81

Q4.24

arrow
arrow

N/A

-0.69
vs -0.57

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+166%

407K  vs 153K

Q4.22

arrow
arrow

+384%

1.6M  vs 333K

Q1.23

arrow
arrow

+456%

967K  vs 174K

Q2.23

arrow
arrow

+64%

268K  vs 163K

Q3.23

arrow
arrow

+273%

1.5M  vs 407K

Q4.23

arrow
arrow

+156%

4.1M  vs 1.6M

Q1.24

arrow
arrow

-84%

156K  vs 967K

Q2.24

arrow
arrow

+832%

2.5M  vs 268K

Q3.24

arrow
arrow

-45%

835.6K  vs 1.5M

Q4.24

arrow
arrow

-80%

825.6K  vs 4.1M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-8%

-0.08
vs -0.14

Q4.22

arrow
arrow

-7%

-0.07
vs -0.08

Q1.23

arrow
arrow

-7%

-0.07
vs -0.07

Q2.23

arrow
arrow

-11%

-0.11
vs -0.07

Q3.23

arrow
arrow

-16%

-0.16
vs -0.11

Q4.23

arrow
arrow

-10%

-0.10
vs -0.16

Q1.24

arrow
arrow

-4%

-0.04
vs -0.10

Q2.24

arrow
arrow

-4%

-0.04
vs -0.04

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

161

161
vs 182

-12%

Q4.22

arrow
arrow

182

182
vs 161

13%

Q1.23

arrow
arrow

169

169
vs 182

-7%

Q2.23

arrow
arrow

161

161
vs 169

-5%

Q3.23

arrow
arrow

158

158
vs 161

-2%

Q4.23

arrow
arrow

177

177
vs 158

12%

Q1.24

arrow
arrow

204

204
vs 177

15%

Q2.24

arrow
arrow

187

187
vs 204

-8%

Earnings Growth

Latest News